Posts Tagged ‘Dr. Nicholas Peppas’
Nicholas Peppas, professor in the McKetta Department of Chemical Engineering at The University of Texas at Austin and an expert in biomaterials and drug delivery systems, has been elected to the American Academy of Arts and Sciences.
Peppas is one of 228 new members elected this year. They include some of the world’s most … Read the rest »
Originally published on the Department of Biomedical Engineering’s website.
Treatment of autoimmune disorders is most effective when they are diagnosed early. In Sjögren’s syndrome, an autoimmune disease that affects the exocrine system, patients suffer from dry eye and dry mouth. Diagnosis is often delayed by six to ten years even after symptoms appear. Currently, … Read the rest »
Today the U.S. Food and Drug Administration approved the drug product Zepatier for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Texas ChE Ph.D. student Angela Wagner of Professor Nicholas Peppas’ research group was one of the team of eight researchers to co-invent and patent Zepatier.
Hepatitis … Read the rest »
Nicholas Peppas, professor in the McKetta Department of Chemical Engineering and director of the Institute of Biomaterials, Drug Delivery and Regenerative Medicine, has received a courtesy appointment in the Dell Medical School’s Department of Surgery and Perioperative Care.
In this role he will facilitate collaborative research between biomedical engineers and physicians to solve … Read the rest »
Nicholas Peppas, the Cockrell Family Regents Chair #6 in Engineering and professor of chemical engineering, biomedical engineering and pharmacy at UT Austin, recently received the 2015 International Award from the European Society for Biomaterials. The award was given at the 27th European Conference on Biomaterials in Krakow, Poland, Sept. 1.
The prestigious accolade … Read the rest »
The Cockrell School of Engineering at The University of Texas at Austin is launching the university’s first health care engineering institute dedicated to developing technologies and treatments that will immediately improve patient quality of life.